Medicon Hellas

Medilyzer series are available for export, along with a dedicated reagents line packed in barcoded instrument-specific vials, under the commercial name MLR.

The Medilyzer series offers biochemistry analyzers for small-to-medium labs, compatible with MLR-brand reagents and designed for ease of use and maintenance.

The measurement of blood gases shows the levels of oxygen and carbon dioxide as well as the acidity (pH) of the blood. The sample is taken from a peripheral artery. This test is mainly used to determine how well the lungs are able to carry oxygen to the circulation and remove carbon dioxide from it.

Hematology analyzers use electrical resistance, flow cytometry, and fluorescence flow cytometry with chemical reagents to measure blood cell parameters.

FILTER TIPS Filter tips 10μl 3735-HFTR0010-96 Package/10 racks(10*96=960 tips) Filter tips 20μl 3735-4330-7139 Package/10 racks(10*96=960 tips) Filter tips 100μl 3735-HFTR0100-96 Package/10 racks(10*96=960 tips) Filter tips 200μl 3735-HFTR0200-96 Package/10 racks (10*96=960 tips) Filter t

Medicon Hellas debuted at CACLP 2024 in Chongqing, showcasing reagents at Mole Bioscience’s booth and gaining recognition from international producers.

Medicon Hellas S.A. will participate in MEDICA 2024 in Düsseldorf, Germany.

Medicon Hellas attended MEDICA TradeFair 2022.

The Board of Directors of MEDICON HELLAS S.A. is the guardian of Corporate Governance. The Board of Directors of the Company consists of three (3) to nine (9) members and is elected by the General Assembly of Shareholders with a term that cannot exceed six (6) years.

Internal audit is conducted by Mr. Antonis Papantoniou, supervised by the Audit Committee. The Internal Auditor has the following responsibilities:

Medicon has a long and mutually profitable cooperation for distribution in Greece with the companies below. New contacts are always welcome.

Contact Person Andreas Stamboulis 210-66606129 staboulis@mediconsa.com

Medicon has a wide range of activities in the IVD sector, including:

Medicon Hellas S.A. reports **EUR 9.52 million in sales** for the half-year ending June 30, 2026, up from **EUR 8.85 million** in the prior-year period. The company’s **net income rises to EUR 1.52 million**, nearly doubling compared to **EUR 0.79 million** in the same period last year. The results reflect improved financial performance in revenue and profitability.

Sep 2026MarketScreenerNews article

Medicon Hellas S.A. declares an annual dividend of **EUR 0.15 per share**, set for payment on **July 17, 2026**. The ex-date is **July 13, 2026**, and the record date is **July 14, 2026**. Shareholders meeting eligibility criteria will receive the payout.

Jun 2026MarketScreenerNews article

Medicon Hellas S.A. reports **EUR 17.95 million in sales** for 2025, a slight decline from EUR 18.12 million in 2024. The company’s **net income rises to EUR 1.73 million**, up from EUR 1.37 million the prior year. The earnings reflect continued profitability amid a marginal drop in revenue.

Apr 2026MarketScreenerNews article

Medicon Hellas reports a **H1 net profit of EUR 0.8 million**, up from EUR 0.2 million in the same period last year. The company’s **EBITDA rises to EUR 1.6 million**, compared to EUR 1.2 million year-over-year, while **turnover reaches EUR 8.8 million**, slightly above the EUR 8.7 million recorded in H1 2022.

Sep 2025MarketScreenerNews article